Combined cord blood and bone marrow transplantation from the same human leucocyte antigen-identical sibling donor for children with malignant and non-malignant diseases


Tucunduva L., Volt F., Cunha R., Locatelli F., Zecca M., Yesilipek A., ...Daha Fazla

BRITISH JOURNAL OF HAEMATOLOGY, cilt.169, ss.103-110, 2015 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 169 Konu: 1
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1111/bjh.13267
  • Dergi Adı: BRITISH JOURNAL OF HAEMATOLOGY
  • Sayfa Sayıları: ss.103-110

Özet

Umbilical cord blood (UCB) from an human leucocyte antigen (HLA)-identical sibling can be used for transplantation of patients with malignant and non-malignant diseases. However, the low cellular content of most UCB units represents a limitation to this approach. An option to increase cell dose is to harvest bone marrow (BM) cells from the same donor and infuse them along with the UCB. We studied 156 children who received such a combined graft between 1992 and 2011. Median age was 7years and 78% of patients (n=122) were transplanted for non-malignant diseases, mainly haemoglobinopathies. Acute leukaemia (n=26) was the most frequent malignant diagnosis. Most patients (91%) received myeloablative conditioning. Median donor age was 17years, median infused nucleated cell dose was 244x10(7)/kg and median follow-up was 41months. Sixty-days neutrophil recovery occurred in 96% of patients at a median of 17d. The probabilities of grade-II-IV acute and chronic graft-versus-host disease (GVHD) were 19% and 10%, respectively. Four-year overall survival was 90% (68% malignant; 97% non-malignant diseases) with 3% probability of death. In conclusion, combined UCB and BM transplantation from an HLA-identical sibling donor is an effective treatment for children with malignant and non-malignant disorders with high overall survival and low incidence of GVHD.